FrancophonIA/ELRC3.0 huggingface dataset:
English: Atorvastatin should be used as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) in these patients or if such treatments are unavailable.
Slovenian: Atorvastatin je treba pri teh bolnikih uporabiti ali kot dodatek drugim načinom terapevtskega zniževanja lipidov (npr. aferezi LDL) ali če takšni načini niso na voljo.
English: Treatment with atorvastatin 80 mg/day increased the time to occurrence of the combined primary endpoint, defined as death from any cause, nonfatal MI, resuscitated cardiac arrest, or angina pectoris with evidence of myocardial ischaemia requiring hospitalization, indicating a risk reduction by 16% (p=0.048).
Slovenian: Zdravljenje z atorvastatinom 80 mg na dan je podaljšalo čas do nastopa sestavljenega primarnega opazovanega dogodka, ki je bil definiran kot smrt zaradi kateregakoli razloga, miokardni infarkt brez smrtnega izida, uspešno oživljanje po zastoju srca ali angina pektoris z znaki ishemije miokarda, zaradi katere je potrebna hospitalizacija, kar kaže na 16-odstotno zmanjšanje tveganja (p = 0,048).
English: Clinical monitoring of these patients is recommended
Slovenian: Priporočeno je klinično spremljanje teh bolnikov.
English: All patients had at least 3 of the pre-defined cardiovascular risk factors: male gender, age ≥55 years, smoking, diabetes, history of CHD in a first-degree relative, TC:HDL-C >6, peripheral vascular disease, left ventricular hypertrophy, prior cerebrovascular event, specific ECG abnormality, proteinuria/albuminuria.
Slovenian: Vsi bolniki so imeli vsaj 3 od naslednjih, vnaprej določenih dejavnikov srčnožilnega tveganja: moški spol, starost ≥ 55 let, kajenje, diabetes, anamnezo koronarne srčne bolezni pri sorodniku v prvem kolenu, razmerje celokupni holesterol: HDL > 6, periferno žilno bolezen, hipertrofijo levega prekata, predhoden možganskožilni dogodek, specifične nenormalnosti EKG ali proteinurijo/albuminurijo.
English: PHARMACEUTICAL FORM Film-coated tablet.
Slovenian: FARMACEVTSKA OBLIKA filmsko obložena tableta [Izpolni država članica]
English: What {PRODUCT NAME} looks like and contents of the pack [To be completed nationally]
Slovenian: Izgled zdravila {(Lastniško) ime} in vsebina pakiranja [Izpolni država članica]
English: If any of these apply to you, your doctor will need to carry out a blood test before and possibly during your {PRODUCT NAME} treatment to predict your risk of muscle related side effects.
Slovenian: Če karkoli od zgoraj naštetega velja za vas, bo vaš zdravnik za oceno tveganja za pojav neželenih učinkov, povezanih z mišicami, izvedel preiskave krvi pred zdravljenjem z zdravilom {(Lastniško) ime} in verjetno tudi med njim.
English: − If muscular symptoms are severe and cause daily discomfort, even if the CK levels are elevated to ≤ 5 x ULN, treatment discontinuation should be considered.
Slovenian: - Če so mišični simptomi hudi in povzročajo težave v vsakodnevnem življenju, je treba razmisliti o prekinitvi zdravljenja tudi, če je vrednost CK  5-kratna ZNM.
English: Women of child-bearing potential should use appropriate contraceptive measures during treatment (see section 4.3).
Slovenian: Ženske v rodni dobi morajo med zdravljenjem uporabljati ustrezno kontracepcijo (glejte poglavje 4.3).
English: If you have any further questions on the use of this medicine or wish to stop your treatment, ask your doctor or pharmacist.
Slovenian: Če ste prenehali jemati zdravilo {(Lastniško) ime} Če imate dodatna vprašanja o uporabi zdravila ali želite prenehati z zdravljenjem, se posvetujte z zdravnikom ali s farmacevtom.
English: Germany, Hungary, Italy, Latvia, Lithuania,
Slovenian: Madžarska, Italija, Latvija, Litva, Poljska,
English: See Section 2 “Take special care with {PRODUCT NAME}” for details
Slovenian: Za podrobnosti glejte poglavje 2 "Bodite posebno pozorni pri jemanju zdravila {(Lastniško) ime}".
English: {PRODUCT NAME} is indicated as an adjunct to diet for reduction of elevated total cholesterol (total-C), LDL-cholesterol (LDL-C), apolipoprotein B, and triglycerides in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (Corresponding to Types IIa and IIb of the Fredrickson classification) when response to diet and other nonpharmacological measures is inadequate.
Slovenian: Zdravilo {(Lastniško) ime} je indicirano kot dodatek k dieti za znižanje zvišanega celotnega holesterola (celotni-H), holesterola LDL (LDL-H), apolipoproteina B in trigliceridov pri odraslih, mladostnikih in otrocih starejših od 10 let s primarno hiperholesterolemijo, vključno s familiarno hiperholesterolemijo (heterozigotna oblika) ali kombinirano (mešano) hiperlipidemijo (kar ustreza tipoma IIa in IIb po Fredricksonovi klasifikaciji), kadar odziv na dieto in druge nefarmakološke ukrepe ni zadosten.
English: If concomitant administration cannot be avoided, a dose reduction and clinical monitoring for efficacy is recommended (see Table 1).
Slovenian: Če se sočasni uporabi ne moremo izogniti, je priporočljivo zmanjšati odmerke in klinično spremljati učinkovitost (glejte Preglednico 1).
English: fold = no change).
Slovenian: 1-krat = ni spremembe).
English: For patients with prior hemorrhagic stroke or lacunar infarct, the balance of risks and benefits of atorvastatin 80 mg is uncertain, and the potential risk of hemorrhagic stroke should be carefully considered before initiating treatment (see section 5.1).
Slovenian: Razmerje tveganj in koristi uporabe atorvastatina v odmerku 80 mg pri bolnikih s predhodno hemoragično možgansko kapjo in lakunarnim infarktom je negotovo; pred uvedbo zdravljenja je treba natančno pretehtati možno tveganje za hemoragično možgansko kap (glejte poglavje 5.1).
English: In the primary prevention trials the dose was 10 mg/day.
Slovenian: V preskušanjih primarne preventive je bil uporabljen odmerek 10 mg/dan.
English: The half-life of inhibitory activity for HMG-CoA reductase is approximately 20 to 30 hours due to the contribution of active metabolites.
Slovenian: Razpolovni čas zavrtja HMG CoA reduktaze znaša zaradi prispevka aktivnih presnovkov približno 20 do 30 ur.
English: Appropriate clinical monitoring is recommended after initiation or following dose adjustments of the inhibitor.
Slovenian: Bolnika je priporočljivo ustrezno klinično spremljati po začetku dajanja zaviralca ali po prilagoditvi njegovih odmerkov.
English: When multiple doses of digoxin and 10 mg atorvastatin were co-administered, steady-state digoxin concentrations increased slightly.
Slovenian: Pri bolnikih, ki so dobili večkratne odmerke digoksina in 10 mg atorvastatina, so se koncentracije digoksina v stanju dinamičnega ravnovesja rahlo povečale.
English: Fusidic acid
Slovenian: Fusidna kislina
English: • inflammation of the nasal passages, pain in the throat, nose bleed
Slovenian: • vnetje nosnih prehodov, bolečine v žrelu, krvavitev iz nosu,
English: Inhibitors of transport proteins (e.g. ciclosporin) can increase the systemic exposure of atorvastatin (see Table 1).
Slovenian: Zaviralci prenašalcev (n. pr. ciklosporin) lahko povečajo sistemsko izpostavljenost atorvastatinu (glejte Preglednico 1).
English: If it is suspected a patient has developed interstitial lung disease, statin therapy should be discontinued.
Slovenian: Če obstaja sum na intersticijsko bolezen pljuč, je treba bolniku ukiniti zdravljenje s statinom.
English: The concurrent use of atorvastatin and fusidic acid is not recommended, therefore, temporary suspension of atorvastatin may be considered during fusidic acid therapy (see section 4.5).
Slovenian: Sočasna uporaba atorvastatina in fusidne kisline ni priporočljiva, zato lahko med zdravljenjem s fusidno kislino razmislimo o začasni prekinitvi uporabe atorvastatina (glejte poglavje 4.5).
English: Concomitant administration of atorvastatin with inducers of cytochrome P450 3A (e.g. efavirenz, rifampin, St. John's Wort) can lead to variable reductions in plasma concentrations of atorvastatin.
Slovenian: Sočasna uporaba atorvastatina z induktorji citokroma P450 3A (n. pr. efavirenza, rifampina, šentjanževke) lahko privede do variabilnih zmanjšanj plazemske koncentracije atorvastatina.
English: The maximum dose is 80 mg once a day.
Slovenian: Največji odmerek je 80 mg enkrat na dan.
English: 6.4 Special precautions for storage This medicinal product does not require any special storage conditions.
Slovenian: 6.4 Posebna navodila za shranjevanje Za shranjevanje niso potrebna posebna navodila.
English: Itraconazole 200 mg OD, 4 days
Slovenian: Itrakonazol 200 mg enkrat na dan , 4 dni
English: LIPITOR and associated names (see Annex I) 10 mg film-coated tablets LIPITOR and associated names (see Annex I) 20 mg film-coated tablets LIPITOR and associated names (see Annex I) 40 mg film-coated tablets LIPITOR and associated names (see Annex I) 80 mg film-coated tablets
Slovenian: LIPITOR in povezana imena (glejte Dodatek I) 10 mg filmsko obložene tablete LIPITOR in povezana imena (glejte Dodatek I) 20 mg filmsko obložene tablete LIPITOR in povezana imena (glejte Dodatek I) 40 mg filmsko obložene tablete LIPITOR in povezana imena (glejte Dodatek I) 80 mg filmsko obložene tablete
English: Atorvastatin produces a profound and sustained increase in LDL receptor activity coupled with a beneficial change in the quality of circulating LDL particles.
Slovenian: Poleg tega močno in dolgotrajno zveča aktivnost receptorjev LDL, kar ugodno vpliva na kakovost krožečih LDL delcev v obtoku.
English: • vomiting, belching, abdominal pain upper and lower, pancreatitis (inflammation of the pancreas leading to stomach pain)
Slovenian: • bruhanje, spahovanje, bolečina v zgornjem in spodnjem delu trebuha pankreatitis (vnetje trebušne slinavke, ki povzroči bolečine v želodcu),
English: As with other HMG-CoA reductase inhibitors elevated serum transaminases have been reported in patients receiving {PRODUCT NAME}.
Slovenian: Tako kot pri drugih zaviralcih HMG CoA reduktaze tudi pri bolnikih, zdravljenih z zdravilom {(Lastniško) ime}, poročajo o zvišanju serumskih transaminaz.
English: Atorvastatin has been shown to reduce concentrations of total-C (30% - 46%), LDL-C (41% - 61%), apolipoprotein B (34% - 50%), and triglycerides (14% - 33%) while producing variable increases in HDLC and apolipoprotein A1 in a dose response study.
Slovenian: V raziskavi odzivanja na odmerjanje je atorvastatin zmanjšal koncentracijo celotnega-H (za 30-46 %), LDL-H (za 41-61 %), apolipoproteina B (za 34-50 %) in trigliceridov (za 14-33 %) obenem pa različno močno zvišal holesterol HDL in apolipoprotein A1.
English: Reproductive system and breast disorders Very rare: gynecomastia.
Slovenian: Motnje reprodukcije in dojk Zelo redko: ginekomastija
English: {PRODUCT NAME} contains lactose.
Slovenian: Zdravilo {(Lastniško) ime} vsebuje laktozo monohidrat.
English: In cases where coadministration with atorvastatin is necessary, lower maintenance doses of atorvastatin are recommended.
Slovenian: V primerih ko je potrebno sočasno odmerjanje z atorvastatinom, so priporočeni nižji vzdrževalni odmerki atorvastatina.
English: The risk of these events may be increased with the concomitant use of fibric acid derivatives and atorvastatin.
Slovenian: Tveganje za pojav teh dogodkov se lahko pri sočasni uporabi derivatov fibrinske kisline in atorvastatina poveča.
English: − Serious illness with severe peeling and swelling of the skin, blistering of the skin, mouth, eyes genitals and fever.
Slovenian: - Huda bolezen z močnim luščenjem in otekanjem kože, nastajanjem mehurjev na koži, ustih, očeh in spolovilih ter zvišana telesna temperatura.
English: The following are reasons why {PRODUCT NAME} may not be suitable for you:
Slovenian: Bodite posebno pozorni pri uporabi zdravila {(Lastniško) ime} Zdravilo {(Lastniško) ime} za vas morda ni primerno iz naslednjih razlogov:
English: • Exceptional cases of interstitial lung disease, especially with long term therapy (see section 4.4).
Slovenian: • izjemni primeri intersticijske bolezni pljuč, zlasti med dolgotrajnim zdravljenjem (glejte poglavje
English: Blood and lymphatic system disorders Rare: thrombocytopenia.
Slovenian: Bolezni krvi in limfatičnega sistema Redko: trombocitopenija
English: The low systemic availability is attributed to presystemic clearance in gastrointestinal mucosa and/or hepatic first-pass metabolism
Slovenian: Majhno sistemsko uporabnost pripisujejo predsistemskemu očistku v sluznici prebavil in/ali jetrni presnovi prvega prehoda.
English: In cases where coadministration with atorvastatin is necessary, do not exceed 10 mg atorvastatin daily.
Slovenian: V primerih ko je potrebno sočasno odmerjanje z atorvastatinom, odmerek ne sme biti večji kot 10 mg.
English: Rifampin 600 mg OD, 5 days (doses separated)
Slovenian: Rifampin 600 mg enkrat na dan, 5 dni (ločeni odmerki)
English: Always take {PRODUCT NAME} exactly as your doctor has told you.
Slovenian: Pri jemanju zdravila {(Lastniško) ime} vedno natančno upoštevajte zdravnikova navodila.
English: There was a 36.4% mean reduction in CRP in the atorvastatin group compared to a 5.2% reduction in the pravastatin group (p<0.0001).
Slovenian: V skupini z atorvastatinom se je CRP v povprečju znižal za 36,4 %, v skupini s pravastatinom pa za 5,2 % (p < 0,0001).
English: Denmark, Greece, Iceland, Portugal, Spain
Slovenian: Danska, Grčija, Islandija, Portugalska, Španija Zarator Finska
English: The median percent change, from baseline, in total atheroma volume (the primary study criteria) was0.4% (p=0.98) in the atorvastatin group and +2.7% (p=0.001) in the pravastatin group (n=249).
Slovenian: Mediani odstotek spremembe celotnega volumna ateroma (ki je bil v študiji primarno merilo) od izhodišča je bil v skupini z atorvastatinom - 0,4% (p = 0,98) in v skupini s pravastatinom + 2,7 % (p = 0,001) (n = 249).
English: {PRODUCT NAME} is also indicated to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolaemia as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) or if such treatments are unavailable.
Slovenian: Zdravilo {(Lastniško) ime} je indicirano tudi za znižanje zvišanega celotnega-H in LDL-H pri odraslih s homozigotno obliko familiarne hiperholesterolemije kot dodatek drugim načinom terapevtskega zniževanja lipidov (npr. aferezi LDL) ali če takšni načini niso na voljo.
English: In this randomised, double- blind, multicenter, controlled clinical trial, IVUS was performed at baseline and at 18 months in 502 patients.
Slovenian: Preiskavo z IVUZ so v tem randomiziranem, dvojno slepem, multicentričnem kontroliranem kliničnem preskušanju opravili pri 502 bolnikih, in sicer na začetku in po 18 mesecih.
English: All cause mortality was 9.1% (216/2365) for atorvastatin versus 8.9% (211/2366) for placebo.
Slovenian: Umrljivost zaradi vseh vzrokov je bila med prejemniki atorvastatina 9,1 % (216/2.365) in med prejemniki placeba 8 9 % (211/2.366).
English: Patients were hypertensive, 40-79 years of age, with no previous myocardial infarction or treatment for angina, and with TC levels ≤6.5 mmol/l (251 mg/dl).
Slovenian: Bolniki so bili hipertenzivni, stari od 40 do 79 let, pred tem niso imeli miokardnega infarkta, se niso zdravili zaradi angine pektoris in so imeli koncentracijo trigliceridov ≤ 6,5 mmol/l (251 mg/dl).
English: In a clinical study in patients receiving chronic warfarin therapy, coadministration of atorvastatin 80 mg daily with warfarin caused a small decrease of about 1.7 seconds in prothrombin time during the first 4 days of dosing which returned to normal within 15 days of atorvastatin treatment.
Slovenian: V klinični študiji z bolniki, ki so prejemali kronično zdraviljenje z varfarinom, je imela sočasna uporaba 80 mg atorvastatina na dan v prvih štirih dneh uporabe za posledico majhno zmanjšanje - približno za 1,7 sekunde - protrombinskega časa; čas se je po 15 dneh zdravljenja z atorvastatinom povrnil na normalno vrednost.
English: However, lipid effects were greater when {PRODUCT NAME} and colestipol were co-administered than when either medicinal product was given alone.
Slovenian: Vendar pa je bilo delovanje na lipide pri sočasnem dajanju zdravila {(Lastniško) ime} in holestipola večje, kot kadar so enega ali drugega bolniku dajali samega.
English: In a post-hoc analysis of stroke subtypes in patients without coronary heart disease (CHD) who had a recent stroke or transient ischemic attack (TIA) there was a higher incidence of hemorrhagic stroke in patients initiated on atorvastatin 80 mg compared to placebo.
Slovenian: Post hoc analiza podvrst možganske kapi pri bolnikih brez koronarne srčne bolezni (Coronary Heart Disease - CHD), ki so pred kratkim imeli možgansko kap ali tranzitorno ishemično atako (TIA), je v primerjavi s placebom pokazala večjo incidenco hemoragične možganske kapi pri bolnikih, ki so zdravljenje začeli z 80 mg atorvastatina.
English: Effect of co-administered medicinal products on atorvastatin
Slovenian: Učinek sočasno uporabljenih zdravil na atorvastatin
English: Concomitant treatment with other medicinal products
Slovenian: Sočasno zdravljenje z drugimi zdravili
English: In addition, in the case of potent CYP3A4 inhibitors, a lower starting dose of atorvastatin should be considered and appropriate clinical monitoring of these patients is recommended (see section 4.5).
Slovenian: Dodatno je v primeru močnih zaviralcev CYP3A4 priporočljiv manjši začetni odmerek atorvastatina in atorvastatina da takšne bolnike ustrezno klinično nadziramo (glejte poglavje 4.5).
English: This medicine does not require any special storage conditions.
Slovenian: Za shranjevanje zdravila {(Lastniško) ime} niso potrebna posebna navodila.
English: 40 mg on day 1, 10 mg on day 20
Slovenian: 40 mg na dan 1, 10 mg na dan 20
English: Strokes (Fatal and non-fatal)
Slovenian: Možganske kapi (s smrtnim izidom in brez njega)
English: {PRODUCT NAME} is contraindicated during pregnancy (see section 4.3).
Slovenian: Zdravilo {(Lastniško) ime} je kontraindicirano med nosečnostjo (glejte poglavje 4.3).
English: Hypercholesterolaemia
Slovenian: Hiperholesterolemija
English: Risk of rhabdomyolysis is increased when atorvastatin is administered concomitantly with certain medicinal products that may increase the plasma concentration of atorvastatin such as potent inhibitors of CYP3A4 or transport proteins (e.g. ciclosporine, telithromycin, clarithromycin, delavirdine, stiripentol, ketoconazole, voriconazole, itraconazole, posaconazole and HIV protease inhibitors including ritonavir, lopinavir, atazanavir, indinavir, darunavir, etc).
Slovenian: Tveganje za rabdomiolizo se zveča, če je atorvastatin uporabljen sočasno z določenimi zdravili, ki lahko povečajo koncentracijo atorvastatina v plazmi, kakršni so močni zaviralci citokroma P450 3A4 (CYP3A4) ali zaviralci prenašalca (npr.: ciklosporin, telitromicin, klaritromicin, delavirdin, stiripentol, ketokonazol, vorikonazol, itrakonazol, posakonazol in zaviralci HIV-proteaze kot so ritonavir, lopinavir, atazanavir, darunavir, itd.).
English: These results are consistent in patients with heterozygous familial hypercholesterolaemia, nonfamilial forms of hypercholesterolaemia, and mixed hyperlipidaemia, including patients with noninsulin-dependent diabetes mellitus.
Slovenian: To velja tako za bolnike s heterozigotno familiarno hiperholesterolemijo, kot za tiste z nefamiliarno hiperholesterolemijo in mešano hiperlipidemijo, vključno z diabetiki tipa 2.
English: − If such symptoms occur whilst a patient is receiving treatment with atorvastatin, their CK levels should be measured.
Slovenian: - Če se takšni simptomi pojavijo med zdravljenjem z atorvastatinom, je treba določiti CK.
English: {PRODUCT NAME} belongs to a group of medicines known as statins, which are lipid (fat) regulating medicines.
Slovenian: Zdravilo {(Lastniško) ime} sodi v skupino zdravil, imenovano statini, ki so zdravila za uravnavanje ravni maščob v krvi.
English: Major cardiovascular events (fatal and non-fatal AMI, silent MI, acute CHD death, unstable angina, CABG, PTCA, revascularization, stroke) MI (fatal and non-fatal AMI, silent MI)
Slovenian: Pomembni srčnožilni dogodki (AMI s smrtnim izidom in brez njega, nemi MI, akutna smrt zaradi koronarne srčne bolezni, nestabilna angina pektoris, CABG, PTCA, revaskularizacija, možganska kap)
English: Mean volume of distribution of atorvastatin is approximately 381 l. Atorvastatin is ≥ 98% bound to plasma proteins.
Slovenian: Atorvastatin je ≥ 98 % vezan na beljakovine v plazmi.
English: & Data given as x-fold change represent a simple ratio between co-administration and atorvastatin alone (i.e., 1
Slovenian: & Podatki so podani kot x-kratna sprememba enostavnega razmerja med sočasno uporabo in uporabo atorvastatina samega (t.j.
English: Heterozygous familial hypercholesterolaemia
Slovenian: Heterozigotna familiarna hiperholesterolemija
English: − If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
Slovenian: - Če katerikoli neželeni učinek postane resen ali če opazite katerikoli neželeni učinek, ki ni omenjen v tem navodilu, obvestite svojega zdravnika ali farmacevta.
English: Safety in pregnant women has not been established.
Slovenian: Varnost zdravila med nosečnostjo ni dokazana.
English: In the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study, the effect of atorvastatin 80 mg daily or placebo on stroke was evaluated in 4731 patients who had a stroke or transient ischemic attack (TIA) within the preceding 6 months and no history of coronary heart disease (CHD).
Slovenian: V študiji SPARCL (Stroke Prevention by Aggressive Reduction in Cholesterol Levels) so vpliv 80 mg atorvastatina na dan oz. placeba na možgansko kap ovrednotili pri 4.731 bolnikih, ki so imeli v preteklih 6 mesecih možgansko kap ali tranzitorno ishemično atako (TIA) in v anamnezi niso imeli koronarne srčne bolezni.
English: Atorvastatin, like other HMG-CoA reductase inhibitors, may in rare occasions affect the skeletal muscle and cause myalgia, myositis, and myopathy that may progress to rhabdomyolysis, a potentially lifethreatening condition characterised by markedly elevated creatine kinase (CK) levels (> 10 times ULN), myoglobinaemia and myoglobinuria which may lead to renal failure.
Slovenian: Tako kot drugi zaviralci 3-hidroksi-3-metil-glutaril-koencim A (HMG-CoA) reduktaze, lahko tudi atorvastatin v redkih primerih prizadene skeletne mišice in povzroči mialgijo, miozitis in miopatijo, ki lahko napreduje v rabdomiolizo - ta je lahko smrtno nevarna, značilni zanjo pa so izrazito zvišanje vrednosti kreatinin kinaze (CK) (> 10-kratna ZNM) - mioglobinemija in mioglobinurija, ki lahko povzroči odpoved ledvic.
English: Atorvastatin is metabolized by cytochrome P450 3A4 (CYP3A4) and is a substrate to transport proteins e.g. the hepatic uptake transporter OATP1B1.
Slovenian: Atorvastatin se presnavlja s citokromom P450 3A4 in je substrat za prenašalce, n. pr. za prenašalec jetrnega privzema OATP1B1.
English: You should maintain a standard cholesterol lowering diet during treatment.
Slovenian: Med zdravljenjem morate vzdrževati s standardno prehrano za zniževanje ravni holesterola.
English: Uncommon: hypoglycaemia, weight gain, anorexia
Slovenian: Občasno: hipoglikemija, povečanje telesne mase, anoreksija
English: Co-administration of {PRODUCT NAME} with an oral contraceptive produced increases in plasma concentrations of norethindrone and ethinyl oestradiol.
Slovenian: Sočasno dajanje zdravila {(Lastniško) ime} s peroralnimi kontraceptivi je imelo za posledico povečane plazemske koncentracije noretindrona in etinilestradiola.
English: Digoxin 0.25 mg OD, 20 days
Slovenian: Digoksin 0,25 mg enkrat na dan, 20 dni
English: In a post-hoc analysis, atorvastatin 80 mg reduced the incidence of ischemic stroke (218/2365, 9.2% vs. 274/2366, 11.6%, p=0.01) and increased the incidence of hemorrhagic stroke (55/2365, 2.3% vs. 33/2366, 1.4%, p=0.02) compared to placebo.
Slovenian: Post hoc analiza je pokazala, da je atorvastatin v odmerku 80 mg v primerjavi s placebom zmanjšal incidenco ishemične možganske kapi (218/2.365, 9,2 % v primerjavi z 274/2.366, 11,6 %, p = 0,01) in povečal incidenco hemoragične možganske kapi (55/2.365, 2,3 % v primerjavi s 33/2.366, 1,4 %, p = 0,02).